530 related articles for article (PubMed ID: 16670731)
1. [The immunotherapy potential of agonistic anti-CD137 (4-1BB) monoclonal antibodies for malignancies and chronic viral diseases].
Alfaro C; Murillo O; Tirapu I; Azpilicueta A; Huarte E; Arina A; Arribillaga L; Pérez-Gracia JL; Bendandi M; Prieto J; Lasarte JJ; Melero I
An Sist Sanit Navar; 2006; 29(1):77-96. PubMed ID: 16670731
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies.
Murillo O; Arina A; Tirapu I; Alfaro C; Mazzolini G; Palencia B; López-Diaz De Cerio A; Prieto J; Bendandi M; Melero I
Clin Cancer Res; 2003 Nov; 9(15):5454-64. PubMed ID: 14654524
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic potential of 4-1BB (CD137) in cancer.
Nam KO; Kang WJ; Kwon BS; Kim SJ; Lee HW
Curr Cancer Drug Targets; 2005 Aug; 5(5):357-63. PubMed ID: 16101383
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic vaccination with tumor cells that engage CD137.
Hellstrom KE; Hellstrom I
J Mol Med (Berl); 2003 Feb; 81(2):71-86. PubMed ID: 12601523
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy with agonistic anti-CD137: two sides of a coin.
Sun Y; Chen JH; Fu Y
Cell Mol Immunol; 2004 Feb; 1(1):31-6. PubMed ID: 16212918
[TBL] [Abstract][Full Text] [Related]
6. Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion.
Zhang H; Knutson KL; Hellstrom KE; Disis ML; Hellstrom I
Mol Cancer Ther; 2006 Jan; 5(1):149-55. PubMed ID: 16432173
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies directed against the T-cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice.
Sabel MS; Conway TF; Chen FA; Bankert RB
J Immunother; 2000; 23(3):362-8. PubMed ID: 10838665
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
[TBL] [Abstract][Full Text] [Related]
9. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice.
Cuadros C; Dominguez AL; Lollini PL; Croft M; Mittler RS; Borgström P; Lustgarten J
Int J Cancer; 2005 Oct; 116(6):934-43. PubMed ID: 15856473
[TBL] [Abstract][Full Text] [Related]
10. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E; Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; Melero I
Eur J Immunol; 2016 Mar; 46(3):513-22. PubMed ID: 26773716
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity.
Kocak E; Lute K; Chang X; May KF; Exten KR; Zhang H; Abdessalam SF; Lehman AM; Jarjoura D; Zheng P; Liu Y
Cancer Res; 2006 Jul; 66(14):7276-84. PubMed ID: 16849577
[TBL] [Abstract][Full Text] [Related]
12. Regulation of follicular dendritic cell networks by activated T cells: the role of CD137 signaling.
Sun Y; Blink SE; Chen JH; Fu YX
J Immunol; 2005 Jul; 175(2):884-90. PubMed ID: 16002686
[TBL] [Abstract][Full Text] [Related]
13. Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS.
Sanmamed MF; Pastor F; Rodriguez A; Perez-Gracia JL; Rodriguez-Ruiz ME; Jure-Kunkel M; Melero I
Semin Oncol; 2015 Aug; 42(4):640-55. PubMed ID: 26320067
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD137 monoclonal antibody promotes the direct anti-tumor effect mediated by peripheral blood-derived human dendritic cells in vitro.
Zhang L; Wang Q; Wang X; Ding P; Song J; Ma C; Sun W
Cell Mol Immunol; 2004 Feb; 1(1):71-6. PubMed ID: 16212924
[TBL] [Abstract][Full Text] [Related]
15. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.
Wilcox RA; Flies DB; Zhu G; Johnson AJ; Tamada K; Chapoval AI; Strome SE; Pease LR; Chen L
J Clin Invest; 2002 Mar; 109(5):651-9. PubMed ID: 11877473
[TBL] [Abstract][Full Text] [Related]
16. Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis.
Sun Y; Lin X; Chen HM; Wu Q; Subudhi SK; Chen L; Fu YX
J Immunol; 2002 Feb; 168(3):1457-65. PubMed ID: 11801689
[TBL] [Abstract][Full Text] [Related]
17. Anti-4-1BB-based immunotherapy for autoimmune diabetes: lessons from a transgenic non-obese diabetic (NOD) model.
Sytwu HK; Lin WD; Roffler SR; Hung JT; Sung HS; Wang CH; Cheng TL; Tsou SC; Hsi SC; Shen KL
J Autoimmun; 2003 Nov; 21(3):247-54. PubMed ID: 14599849
[TBL] [Abstract][Full Text] [Related]
18. Second- and third-generation drugs for immuno-oncology treatment-The more the better?
Dempke WCM; Fenchel K; Uciechowski P; Dale SP
Eur J Cancer; 2017 Mar; 74():55-72. PubMed ID: 28335888
[TBL] [Abstract][Full Text] [Related]
19. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner.
Miller RE; Jones J; Le T; Whitmore J; Boiani N; Gliniak B; Lynch DH
J Immunol; 2002 Aug; 169(4):1792-800. PubMed ID: 12165501
[TBL] [Abstract][Full Text] [Related]
20. CD137-mediated T cell co-stimulation terminates existing autoimmune disease in SLE-prone NZB/NZW F1 mice.
Foell J; McCausland M; Burch J; Corriazzi N; Yan XJ; Suwyn C; O'Neil SP; Hoffmann MK; Mittler RS
Ann N Y Acad Sci; 2003 Apr; 987():230-5. PubMed ID: 12727643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]